BOVE, MARILISA
 Distribuzione geografica
Continente #
NA - Nord America 2.531
AS - Asia 2.480
EU - Europa 1.625
SA - Sud America 151
AF - Africa 122
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.912
Nazione #
US - Stati Uniti d'America 2.502
CN - Cina 709
SG - Singapore 700
VN - Vietnam 511
GB - Regno Unito 404
IT - Italia 279
DE - Germania 231
HK - Hong Kong 180
SE - Svezia 167
FR - Francia 130
IN - India 123
BR - Brasile 100
UA - Ucraina 82
RU - Federazione Russa 71
KR - Corea 67
IE - Irlanda 66
CI - Costa d'Avorio 48
NL - Olanda 43
JP - Giappone 34
ZA - Sudafrica 34
JO - Giordania 31
EE - Estonia 30
BG - Bulgaria 23
AR - Argentina 22
TG - Togo 22
BD - Bangladesh 18
CH - Svizzera 18
MX - Messico 17
GR - Grecia 16
IQ - Iraq 16
TH - Thailandia 15
FI - Finlandia 13
ID - Indonesia 13
CL - Cile 12
PH - Filippine 12
TR - Turchia 11
ES - Italia 10
RO - Romania 9
AT - Austria 8
PK - Pakistan 8
SC - Seychelles 7
BE - Belgio 6
CA - Canada 6
EC - Ecuador 6
PL - Polonia 6
UZ - Uzbekistan 5
VE - Venezuela 5
SA - Arabia Saudita 4
CO - Colombia 3
IR - Iran 3
KE - Kenya 3
LT - Lituania 3
MY - Malesia 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
AZ - Azerbaigian 2
EG - Egitto 2
HR - Croazia 2
IL - Israele 2
KZ - Kazakistan 2
OM - Oman 2
RS - Serbia 2
SV - El Salvador 2
TW - Taiwan 2
UY - Uruguay 2
AD - Andorra 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BW - Botswana 1
CG - Congo 1
CM - Camerun 1
CR - Costa Rica 1
HN - Honduras 1
HU - Ungheria 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LU - Lussemburgo 1
MA - Marocco 1
MK - Macedonia 1
MN - Mongolia 1
MU - Mauritius 1
NO - Norvegia 1
PE - Perù 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.912
Città #
Singapore 468
Southend 352
Fairfield 246
Ashburn 239
Santa Clara 184
Hong Kong 174
Hefei 149
San Jose 149
Chandler 137
Ho Chi Minh City 132
Woodbridge 128
Hanoi 110
Seattle 106
Houston 100
Wilmington 95
Princeton 92
Cambridge 91
Beijing 70
Ann Arbor 67
Dublin 65
Dong Ket 60
Boardman 59
Seoul 59
Lauterbourg 55
Abidjan 48
The Dalles 47
Turin 47
Jacksonville 45
Westminster 39
Nanjing 36
Buffalo 35
Berlin 34
Los Angeles 33
Amman 31
Padova 30
Tokyo 30
Bremen 28
Milan 28
Lomé 22
Sofia 22
Bologna 20
Council Bluffs 18
Da Nang 18
Hebei 18
Jinan 18
Bengaluru 17
Dearborn 17
Rome 17
Saint Petersburg 17
Bern 16
Guangzhou 16
Hải Dương 15
San Diego 14
Nanchang 13
Shanghai 13
São Paulo 13
Changsha 11
Des Moines 11
New York 11
Shenyang 11
Zhengzhou 11
Dallas 10
Mexico City 10
Haiphong 9
Redondo Beach 9
Taizhou 9
Bangkok 8
Helsinki 8
London 8
Medford 8
Orem 8
Paris 8
Chicago 7
Olalla 7
Baghdad 6
Redwood City 6
Wuhan 6
Xi'an 6
Athens 5
Brescia 5
Brussels 5
Bühl 5
Düsseldorf 5
Falkenstein 5
Falls Church 5
Frankfurt am Main 5
Groningen 5
Ha Long 5
Hangzhou 5
Jakarta 5
Jiaxing 5
Mahé 5
Moscow 5
Mountain View 5
Ningbo 5
Nuremberg 5
Rio de Janeiro 5
Shijiazhuang 5
Tashkent 5
Tianjin 5
Totale 4.500
Nome #
Effect of Dietary Supplementation with Eufortyn® Colesterolo Plus on Serum Lipids, Endothelial Reactivity, Indexes of Non-Alcoholic Fatty Liver Disease and Systemic Inflammation in Healthy Subjects with Polygenic Hypercholesterolemia: The ANEMONE Study. Nutrients. 2022 May 18;14(10):209 240
Is it Possible to Significantly Modify Blood Pressure with a Combined Nutraceutical on Top of a Healthy Diet? The Results of a Pilot Clinical Trial 211
A comparison study of Lp(a) plasma levels distributions between normo- and hypertensive subjects with high BMI. 184
Sources of variabilità of plasma HDL-cholesterol levels. 179
An evidence-based review on urate-lowering treatments: Implications for optimal treatment of chronic hyperuricemia 173
Serum uric acid change and modification of blood pressure and fasting plasma glucose in an overall healthy population sample: data from the Brisighella heart study 165
Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation 153
Gender-specific haemodynamic and metabolic effects of a sequential training programme on overweight-obese hypertensives. 147
Novel mutation in the ApoB Gene (Apo B-15.56): A Case Report. 146
Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial 141
Effetto di un nutraceutico combinato su sintomi menopausali e fattori di rischio cardiometabolici in donne dislipidemiche affette da sindrome perimenopausale 139
Coenzyne Q10 effect on the serum creatinine increase associated to rosuvastatin 20 mg in severe hypercholesterolemic patients 138
Efficacy and safety of Armolipid Plus®: an updated PRISMA compliant systematic review and meta-analysis of randomized controlled clinical trials. 138
Short-Term Impact of a Combined Nutraceutical on Cognitive Function, Perceived Stress and Depression in Young Elderly with Cognitive Impairment: A Pilot, Double-Blind, Randomized Clinical Trial 136
LDL-oxidation, serum uric acid and pulse-wave velocity relationship in chronic kidney disease: Data from the Brisighella heart study cohort 133
Psychosocial factors and metabolic parameters: is there any association in elderly people? The Massa Lombarda Project 133
null 131
A nutraceutical based approach to reduce cholesterolemia in patients previously intolerant to more than a statin: a pilot study. 128
LDL-oxidation, serum uric acid, kidney function and pulse-wave velocity: Data from the Brisighella Heart Study cohort 125
Omega 3 polyunsaturated fatty acids supplementation and blood pressure levels in hypertriglyceridemic patients with untreated normal-high blood pressure and with or without metabolic syndrome: a retrospective study. 124
Regression of atherosclerosis after one year of treatment with low dosed rosuvastatin: the role of patient selection. 122
Estimating the burden of hyperlipidemia in a hypertensive ambulatory population 121
Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic 119
MMP-2, MMP-9 and their inhibitors in FCH, MS, FCH+MS and control subjects: a comparison study. 119
Effect of quantitative and qualitative diet prescription on children behavior after diagnosis of heterozygous familial hypercholesterolemia. 117
Three-arm, placebo-controlled, randomized clinical trial evaluating the metabolic effect of a combined nutraceutical containing a bergamot standardized flavonoid extract in dyslipidemic overweight subjects. 117
Impact of a short-term synbiotic supplementation on metabolic syndrome and systemic inflammation in elderly patients: a randomized placebo-controlled clinical trial. 116
Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome. 115
Prevalent seasoning and cooking fats, arterial stiffness and lipid pattern in a rural population sample: data from the Brisighella Heart Study 114
Emerging drugs for the treatment of hypercholesterolemia 113
Effect of Synaid on cognitive functions and mood in elderly subjects with self-perceived loss of memory after COVID-19 infection 110
Effects of a Combined Nutraceutical on Lipid Pattern, Glucose Metabolism and Inflammatory Parameters in Moderately Hypercholesterolemic Subjects: A Double-blind, Cross-over, Randomized Clinical Trial 109
Role of olive oil in the health: results form the Eurolive Study. 108
Non conventional cardiovascular risk factors distribution in FCH, MS, FCH+MS and control subjects: towards a full disease characterization. 108
Effect of a sequential training program on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome 105
CARDIOVASCULAR DISEASE RISK PERCEPTION IN PATIENTS AFFECTED BY FAMILIAL HYPERLIPIDAEMIAS IN SPECIALIST SETTING 103
EFFECT OF QUANTITATIVE AND QUALITATIVE DIET PRESCRIPTION ON CHILDREN BEHAVIOUR AFTER A DIAGNOSIS OF FAMILIAL DYSLIPIDEMIA 101
null 98
Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. 95
null 93
Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate 92
Short-Term Effects of Dry Extracts of Artichokeand Berberis in Hypercholesterolemic Patients Without Cardiovascular Disease 91
Successful treatment of a patient with mitochondrial myopathy with alirocumab 91
Prevalence of Hypo- and Hyperalphalipoproteinemia according to different diagnostic criteria in the massa lombarda project cohort 90
Evaluation of the short term efficacy and tolerability of a combined nutraceutical with lipid lowering properties: a randomized clinical trial. 87
Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia. 86
Efficacy of soluble fiber supplementation in CVD risk management of patients affected by metabolic syndrome: A 6-months, open-label, RCT 84
null 82
NUTRACEUTICAL EFFECTS ON GLUCOSE AND LIPID METABOLISM IN PATIENTS WITH IMPAIRED FASTING GLUCOSE: A PILOT, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL 80
null 75
null 73
Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia 73
null 71
Effect of a combined mulberry-sage dietary supplement on food craving and body weight: a pilot clinical trial 69
Different effect of psyllium and guar dietary supplementation on blood pressure control in hypertensive overweight patients: a six-month, randomized clinical trial. 69
null 68
null 64
MMP-2, MMP-9 and their inhibitors and other prothrombotic risk factors plasma level in FCH, MS, FCH plus MS and control subjects 62
null 62
Nutraceutical Effects on Glucose and Lipid Metabolism in Patients with Impaired Fasting Glucose: A Pilot, Double-Blind, Placebo-Controlled, Randomized Clinical Trial on a Combined Product 62
The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function 57
Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease Risk: A Double-Blind, Placebo-Controlled Randomized Clinical Trial 54
null 51
Detection of familial combined hyperlipoproteinaemia patients in the Brisighella Heart Study historical cohort: An epidemiological approach 48
Sources of variability of plasma HDL-cholesterol levels. 37
Totale 7.045
Categoria #
all - tutte 18.932
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.932


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021156 0 0 0 0 0 0 0 0 0 37 24 95
2021/2022737 73 17 40 26 83 50 9 37 38 24 214 126
2022/2023856 65 94 25 139 57 53 33 43 190 37 83 37
2023/2024196 4 45 17 26 15 34 12 20 2 15 3 3
2024/20251.087 24 134 88 56 257 68 91 24 5 53 40 247
2025/20262.423 205 311 249 172 285 159 258 159 438 187 0 0
Totale 7.045